TMDXTransMedics Group, Inc.

Sector: Medical Devices / Organ Transplant Technology Form: 10-Q | Filed with the SEC on: November 5, 2026

---

What Happened

TransMedics Group, Inc. (TMDX) filed its 10-Q quarterly report with the SEC on November 5, 2026, disclosing financial results for the third quarter of fiscal year 2026. The company reported revenues of $444.7 million, operating income of $87.3 million, and net income of $25.7 million for the quarter. Diluted earnings per share came in at $2.28, with basic EPS of $2.50, marking a substantial step forward for a company whose comparable revenue base in Q3 FY2022 stood at just $21.7 million — underlining the dramatic scale of commercial expansion over four fiscal years.

---

Why It Matters

The headline numbers represent a material inflection for TMDX investors:

• Revenue of $444.7M in a single quarter signals that TransMedics' Organ Care System (OCS) platform and its aviation logistics network have achieved a scale that was not widely anticipated at this stage of the company's commercial build-out.
• Operating income of $87.3M demonstrates meaningful operating leverage — the business is now generating substantial profit at the operating line, not merely growing the top line.
• Net income of $25.7M (diluted EPS: $2.28) confirms that profitability has fully arrived, clearing one of the key transitional milestones investors had been watching.
• The market's immediate response — shares up 26.18% to $87.04 on the filing date — reflects that these results appear to have significantly exceeded prevailing expectations.

The contrast with Q3 FY2022 revenues of $21.7 million puts the trajectory in sharp relief: in roughly four years, quarterly revenues have grown approximately 20-fold.

---

Analysis

The magnitude of the revenue figure — $444.7 million in a single quarter — combined with a positive operating income of $87.3 million suggests TransMedics has crossed a critical threshold: the OCS platform and its integrated logistics operations are no longer a growth story with uncertain profitability; they are a scaled commercial business generating real operating cash flows. The gap between operating income ($87.3M) and net income ($25.7M) warrants attention and likely reflects below-the-line charges — interest expense, tax items, or other non-operating costs — that investors will want to examine in detail within the full 10-Q filing.

The 26% single-day stock move is extraordinary for a company of this profile and strongly suggests the results surprised the market to the upside. Key questions to watch going forward include:

• Sustainability of revenue run-rate: Whether the $444.7M quarter reflects a durable new baseline or was influenced by any one-time volume factors.
• Margin trajectory: Whether operating margins can be maintained or expanded from this level as the logistics network scales.
• Path from operating income to net income: Narrowing the gap between $87.3M operating income and $25.7M net income would be a significant value catalyst.
• Competitive positioning: As OCS adoption broadens, the response from hospital systems, payers, and any emerging competitors will shape the medium-term outlook.

This filing marks a genuinely significant moment in TransMedics' commercial history. The operating leverage visible in these numbers makes the next two to three quarters of results particularly important to watch.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from TransMedics Group's SEC filing and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is expressed or implied. Investors should read the full 10-Q filing and consult a qualified financial advisor before making investment decisions.

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1756262/000119312526449827/tmdx-20260930.htm